Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00095901 · ClinicalTrials.gov registry record · Phase 2

Capecitabine For Nasopharyngeal Cancer

A Phase 2 study of Head and Neck Cancer, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
Phase 2
Development phase
3
Enrollment target
3
Study locations

NCT00095901 is a Phase 2 study of Head and Neck Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 3 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00095901, a Phase 2 study of Head and Neck Cancer, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
Phase 2
Development phase
3 participants
Enrollment target
3
Study locations

Study Summary

This study plans to examine the effects of Capecitabine administered as an oral chemotherapy drug in participants with nasopharyngeal cancer. Capecitabine is an oral prodrug. A "prodrug" is a drug that is converted within the body into its active form that has medical effects. Capecitabine is a prodrug of 5-fluorouracil (5-FU), which is a chemotherapy agent frequently used to treat head and neck cancers. Capecitabine is absorbed through the gastrointestinal tract and is converted to 5-FU. Capecitabine (Xeloda9) has been tested in subjects with colorectal and breast cancers, and shown to be effective in those cancers. Likewise, 5-FU has shown benefit when administered as a continuous infusion for those with nasopharyngeal cancers. Since Capecitabine is a prodrug of 5-FU, it is possible that similar results will be achieved. RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have locally recurrent or metastatic nasopharyngeal cancer.

Conditions Studied

Head and Neck Cancer

Interventions

  • DRUG Capecitabine

Study Locations (3)

Massachusetts

  • Massachusetts General Hospital Cancer Center - Boston
  • Dana Farber Cancer Institute - Boston

Illinois

  • University of Chicago Cancer Research Center - Chicago

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2004-06
Est. Completion 2007-05
Phase Phase 2

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00095901

The ClinicalTrials.gov registry entry for NCT00095901 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which Capecitabine is the first listed.

NCT00095901 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Illinois.

Frequently Asked Questions

What is clinical trial NCT00095901 about?

NCT00095901 is a clinical study titled "Capecitabine For Nasopharyngeal Cancer". This study plans to examine the effects of Capecitabine administered as an oral chemotherapy drug in participants with nasopharyngeal cancer. Capecitabine is an oral prodrug. A "prodrug" is a drug that is converted within the body into its active form that has medical effects. Capecitabine is a pro...

What is the current status of trial NCT00095901?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2004-06. Estimated completion is 2007-05.

What conditions does trial NCT00095901 study?

This clinical trial studies the following conditions: Head and Neck Cancer.

What interventions are being tested in trial NCT00095901?

The interventions under investigation include: Capecitabine (DRUG).

Who is sponsoring clinical trial NCT00095901?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00095901 being conducted?

This trial has 3 study locations across Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Head and Neck Cancer

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.